GlobeNewswire by notified

Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients

Share

February 27, 2024

New image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system. Designed to streamline neurovascular procedures and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Minimally invasive procedures enabled by interventional systems like Azurion are a key part of the diagnosis and treatment pathway for stroke, where every minute counts in conserving the patient’s quality-of-life. Interventional systems are also used to precisely plan and carry out complex neurovascular procedures such as the repair of brain aneurysms and birth defects. By allowing neuro interventionists to treat more patients, more efficiently, with potentially better outcomes, the new Philips Azurion neuro biplane system enhances both the staff and patient experience and contributes to lower cost of care.

“Working closely with leading interventionists, we designed the latest Azurion neuro biplane to meet their requirements of superior patient care, optimized angio suite performance, and efficient return on investment,” said Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips. “Together, I am confident we can continue to reduce the impact of stroke, helping more patients to recover faster and reducing long-term impact on their health.”

Philips’ Azurion neuro biplane image-guided therapy system is designed to smooth and optimize procedure workflows where a combination of 2D and 3D imaging is needed for confident diagnosis and precision treatment. Used with the company’s latest Neuro Suite software and services, it provides neuro interventionists with a fully integrated solution that combines Philips’ world-class ClarityIQ low dose imaging with a range of neuro dedicated tools* and value-added services that offer unprecedented levels of efficiency, flexibility, and control.

New features in the Azurion neuro biplane system include enhanced C-arm rotation, angulation (imaging angles), and parking facilities that allow rapid transitioning between 2D to 3D imaging, comprehensive table-side control that eliminates the need to leave the sterile field, automatic beam rotation to obtain correctly oriented images for every angulation and rotation, and a new head immobilizer to support enhanced stroke care.

Accelerating treatment for stroke
One in four adults over the age of 25 will have a stroke at some point in their lives [1]. Globally, the direct and indirect cost has been estimated at around USD 891 billion per year [2]. The key to reducing the personal, societal, and financial impact of stroke is to follow the axiom ‘time-is-brain’. The faster stroke is treated, the better the potential outcome.

For ischemic stroke, which accounts for 87% of all strokes [3], the benefits of delivering intra-arterial treatment (IAT) – catheter-based procedures to mechanically disrupt or remove blood clots (mechanical thrombectomy) and/or inject clot-busting agents – within 6 hours of symptom onset, are widely accepted [4]. With mechanical thrombectomy becoming the standard for treating large vessel occlusion (LVO) ischemic stroke, the demand for high utilization angio suites that allow interventionists to operate with speed and efficiency has rapidly increased.

In addition to the efficiency enhancing features of its Azurion platform, Philips is maximizing the up-time of its angio suite solutions by using AI and machine learning to monitor system performance through the new remote connection services of the Philips ServiceHub. These services communicate, monitor, and proactively respond to potential service issues – for example, predicting likely component failures at least 7 days in advance so that pre-emptive action can be taken.

With its comprehensive stroke care portfolio, Philips is connecting the dots between caregivers – wherever they are – at every vital step in the stroke care pathway. The result is smart stroke solutions designed to support connected care. Visit Philips at #ECR2024 for more information.

*SmartCT Soft Tissue, SmartCT Angio, SmartCT Roadmap, SmartCT Vaso, AneurysmFlow 
[1] World Stroke Organization (WSO): Global Stroke Fact Sheet 2022 (https://www.world-stroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf)
[2] Owolabi MO, Thrift AG, Mahal A, et al.; Stroke Experts Collaboration Group. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health. 2022 Jan;7(1):e74-e85. doi: 10.1016/S2468-2667(21)00230-9. Epub 2021 Oct 29. Erratum in: Lancet Public Health. 2022 Jan;7(1):e14. PMID: 34756176; PMCID: PMC8727355. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00230-9/fulltext
[3] Virani S.S., Alonso A., Benjamin E.J., et al. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000757?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
[4] NHS England UK : https://www.england.nhs.uk/wp-content/uploads/2019/05/Mechanical-thrombectomy-for-acute-ischaemic-stroke-ERRATA-29-05-19.pdf
[5] WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment). Sponsored by Philips. https://www.wetrust-study.com/

For further information, please contact:
Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction, Clarification, Disclaimer, Disclosure and Forward-Looking Information on Previously Released Statements by C.K. McWhorter, McWhorter Foundation, McWhorter Foundation Inc. & CTRL USA, CTRL USA LLC, McWhorter Trust, McWhorter Family Trust, Carter Kennedy Equity Partners, Commitment to Transparency13.4.2024 13:59:53 CEST | Press release

PALM BEACH, Fla., April 13, 2024 (GLOBE NEWSWIRE) -- In our previous communications, particularly the statements dated Nov 13, 2019, Nov 23, 2020, Nov 27, 2020, July 14, 2020, Mon, Apr 12, 2021, June 07, 2021, March 29, 2021, March 31, 2021, April 20, 2023, March 17, 2024 information was provided concerning events & or residential real estate transactions. It has come to our attention that some of these statements were inaccurately presented as completed events and also included projections that have not yet been realized. Correction and Clarification: We regret any confusion caused by the inaccuracies and the premature or accidental announcement of mock releases & or future plans. We are issuing this statement to correct and clarify. The events described as having occurred have not yet taken place. The forward-looking statements regarding were intended to be held in house as mock press releasesForward-Looking Statements: This press release contains forward-looking statements within th

Nokia Corporation: Repurchase of own shares on 12.04.202412.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 12 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 12.04.2024 Espoo, Finland – On 12 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,4733.19CEUX--BATE--AQEU--TQEX--Total557,4733.19 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

EPH European Property Holdings PLC Suggests Amendments to the Terms of its Listed Bonds ISIN CH117734830212.4.2024 20:00:00 CEST | Press release

12th April 2024, Limassol, Cyprus I Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (the “Company” or “EPH”) has decided to suggest to the holders of the Company’s bonds with ISIN CH1177348302 and with a total nominal value of EUR 122,175,000 to amend certain terms of these bonds: Replacement of the current interest rate of 2.25 % p.a. with an interest rate of 3.50% p.a.; andA term prolongation of 5 years of the Bonds until 31 May 2029 The bondholders are requested to consent or reject the suggested amendments until 13th May 2024. Subject to having received consents by all bondholders the amendments to the Terms of the Bonds shall become effective on 1st June 2024. EPH EUROPEAN PROPERTY HOLDINGS PLC is an investment company listed on SIX Swiss Exchange and holds a commercial property portfolio with a total value of approx. EUR 900 million, including real estate assets in Berlin, Hamburg, Stuttgart, Dresden, Switzerland and Vienna. Additional information on

Nexstim Plc Resolved on a New Stock Option Plan 2024H12.4.2024 20:00:00 CEST | Press release

Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim resolved on 12 April, 2024, to launch a new stock option plan 2024H aimed at the Board of Directors of the Company by virtue of an authorization granted by the Annual General Meeting of Shareholders of the company on March 28, 2024, and according to the AGM resolution. The Company has a weighty financial reason for the issue of stock options since the stock options are intended to form part of the incentive and commitment program. The purpose of the stock options is to encourage the members of the Board of Directors to work and co-operate on a long-term basis to increase shareholder value. The purpose of the stock options is also to commit the members of the Board of Directors to the Company. The maximum total number of stock options 2024H issued is 37,500 and they entitle the

SalMar - Nøkkelinformasjon ved kontantutbytte for SalMar ASA12.4.2024 19:16:00 CEST | Pressemelding

Utbyttebeløp: 35,0 kroner per aksje Annonsert valuta: NOK Siste dag inklusive: 06.06.2024 Ex-dato: 07.06.2024 Record date (eierregisterdato): 10.06.2024 Betalingsdato: På eller omkring: 20.06.2024 Vedtaksdato: 06.06.2024 For mer informasjon, kontakt: Håkon Husby, IR-ansvarlig Tel: +47 936 30 449 Email: hakon.husby@salmar.no Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

HiddenA line styled icon from Orion Icon Library.Eye